Search results

Oxford BioMedica plc Management and Board change

--Appointment of new Chief Financial Officer and Company Secretary --

http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-plc-management-and-board-change-0

Oxford BioMedica Announces Interim Update on ProSavin® Phase I/II Study in Parkinson's Disease

-- Positive review of all patient cohorts by Data Monitoring Committee --

http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-announces-interim-update-prosavin%C2%AE-phase-iii-study

Oxford BioMedica Interim Management Statement November 2011

 

http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-interim-management-statement-november-2011

Oxford BioMedica Announces Research and Development Collaboration for Glaucoma

-- Research and development agreement signed with Mayo Clinic --

http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-announces-research-and-development-collaboration-glaucoma

Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B

 

http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-announces-us-ind-approval-novel-ocular-product-usher

Oxford BioMedica plc Interim Results for the Six Months Ended 30 June 2011

 

http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-plc-interim-results-six-months-ended-30-june-2011

Oxford BioMedica Announces Interim Data from Highest (5x) Dose Cohort in ProSavin® Phase I/II Study in Parkinson's Disease

 

http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-announces-interim-data-highest-5x-dose-cohort-prosavin%C2%AE

Oxford BioMedica Announces Ocular Programme Update

 

http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-announces-ocular-programme-update

Oxford BioMedica Announces 5T4 Antibody Research Collaboration with ImaginAb

-- ‘In vivo’ diagnostic rights granted for cancer imaging --

http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-announces-5t4-antibody-research-collaboration-imaginab

Oxford BioMedica Plc Management and Board Changes

--Oxford BioMedica Appoints Alex Lewis as Director of Corporate Activities and Strategy--

http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-plc-management-and-board-changes

Pages